Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...
Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that ...
The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...
A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active ...
March 30 () - Viridian Therapeutics said on Monday its experimental drug met the main goal when tested in patients ...
Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results